Jesse Nussbaum, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
AddressLocation Required, #001
Varies CA 00000
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Duke UniversityM.D.2004School of Medicine

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Interaction between innate and Th2 lymphocytes in helminth immunity
    NIH K08AI113143Jun 1, 2014 - May 31, 2019
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial. J Clin Sleep Med. 2024 Dec 01; 20(12):1905-1913. Robbins JA, Sands S, Maganti L, Crumley T, Fox-Bosetti S, Hussain A, Schwartz H, Safirstein B, Ahmad M, Dragone L, Nussbaum J, Kushida C, Iwamoto M, Stoch SA. PMID: 39069967; PMCID: PMC11609840.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults. J Clin Pharmacol. 2024 08; 64(8):1023-1029. Nussbaum JC, Hussain A, Butera P, Ford AP, Kitt MM, O'Neill EA, Smith S, Vargas G, O'Reilly T, Wynne C, Stoch SA, Iwamoto M. PMID: 38651193.
      View in: PubMed   Mentions:    Fields:    
    3. Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults. Vaccine. 2023 Oct 20; 41(44):6488-6501. Nussbaum J, Cao X, Railkar RA, Sachs JR, Spellman DS, Luk J, Shaw CA, Cejas PJ, Citron MP, Al-Ibrahim M, Han D, Pagnussat S, Stoch SA, Lai E, Bett AJ, Espeseth AS. PMID: 37777449.
      View in: PubMed   Mentions: 6     Fields:    
    4. Considerations for Cell and Gene Therapy Programs Entering the Clinical Space. Clin Pharmacol Ther. 2023 09; 114(3):569-577. Walford GA, Bautmans A, Cannon C, Duncan KE, Deschamps K, Matthews RP, Nussbaum J, Stoch SA. PMID: 37309988.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixant. CPT Pharmacometrics Syst Pharmacol. 2023 08; 12(8):1107-1118. Chawla A, Largajolli A, Hussain A, Kleijn H, Ait-Oudhia S, Anton J, Krishna Ananthula H, Nussbaum J, La Rosa C, Gheyas F. PMID: 37147897; PMCID: PMC10431053.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. Transition of care in inborn errors of immunity: Outcomes of a single-center quality improvement initiative. J Allergy Clin Immunol Pract. 2023 07; 11(7):2245-2247.e1. Sanchez LA, Tang M, Ahmed A, Nussbaum JC, Nguyen DN, Muskat M, Chen XH, Pham MN. PMID: 37119980; PMCID: PMC11142330.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs. Clin Transl Sci. 2023 05; 16(5):723-741. Pruimboom-Brees IM, Gupta S, Chemuturi N, Booler HS, Nimz E, Ferrell Ramos M, Caruso A, Maass KF, Bantseev V, Huang Q, Choules MP, Nussbaum JC, Kanodia J, Thompson C, Durairaj C. PMID: 36651217; PMCID: PMC10175998.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist. J Clin Pharmacol. 2022 11; 62(11):1435-1444. Nussbaum JC, Hussain A, Min KC, Marbury TC, Lasseter K, Stoch SA, Iwamoto M. PMID: 35656754.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    9. A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults. Lung. 2022 06; 200(3):315-323. Nussbaum J, Hussain A, Ford A, Butera P, Kitt M, Smith S, Stoch A, Iwamoto M. PMID: 35670873.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough. Clin Pharmacol Drug Dev. 2022 09; 11(9):1054-1067. Gupta P, Hussain A, Ford AP, Smith S, Nussbaum JC, Stoch A, Iwamoto M. PMID: 35510785; PMCID: PMC9540877.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans. Pharmacol Res Perspect. 2022 02; 10(1):e00924. Nussbaum JC, Hussain A, Ma B, Min KC, Chen Q, Tomek C, Iwamoto M, Stoch SA. PMID: 35106949; PMCID: PMC8929362.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    12. Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist. Clin Pharmacol Drug Dev. 2022 01; 11(1):123-128. Nussbaum JC, Hussain A, Ma B, Min KC, Evers R, Li Y, Garrett G, Stoch SA, Iwamoto M. PMID: 34145987.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    13. Tissue-Resident Group 2 Innate Lymphoid Cells Differentiate by Layered Ontogeny and In Situ Perinatal Priming. Immunity. 2019 06 18; 50(6):1425-1438.e5. Schneider C, Lee J, Koga S, Ricardo-Gonzalez RR, Nussbaum JC, Smith LK, Villeda SA, Liang HE, Locksley RM. PMID: 31128962; PMCID: PMC6645687.
      View in: PubMed   Mentions: 121     Fields:    Translation:AnimalsCells
    14. Tissue signals imprint ILC2 identity with anticipatory function. Nat Immunol. 2018 10; 19(10):1093-1099. Ricardo-Gonzalez RR, Van Dyken SJ, Schneider C, Lee J, Nussbaum JC, Liang HE, Vaka D, Eckalbar WL, Molofsky AB, Erle DJ, Locksley RM. PMID: 30201992; PMCID: PMC6202223.
      View in: PubMed   Mentions: 223     Fields:    Translation:AnimalsCells
    15. 1021 Origin of type 2 innate lymphoid cells in the skin. Journal of Investigative Dermatology. 2018 May 1; 138(5):s173. Lee LJ, Schneider SC, Liang LH, Ricardo-Gonzalez RR, Nussbaum NJ, Smith SL, Villeda VS, Locksley LR. .
      View in: Publisher Site   Mentions:
    16. Isolation and Identification of Group 2 Innate Lymphoid Cells in Settings of Type 2 Inflammation. Methods Mol Biol. 2018; 1799:93-107. Nussbaum JC, Ortiz-Carpena JF. PMID: 29956147.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    17. LB973 Characterization of tissue-resident ILC2 heterogeneity in homeostasis. Journal of Investigative Dermatology. 2017 Oct 1; 137(10):b8. Ricardo-Gonzalez RR, Van Dyken VS, Molofsky MA, Nussbaum NJ, Lee LJ, Locksley LR. .
      View in: Publisher Site   Mentions:
    18. A tissue checkpoint regulates type 2 immunity. Nat Immunol. 2016 Dec; 17(12):1381-1387. Van Dyken SJ, Nussbaum JC, Lee J, Molofsky AB, Liang HE, Pollack JL, Gate RE, Haliburton GE, Ye CJ, Marson A, Erle DJ, Locksley RM. PMID: 27749840; PMCID: PMC5275767.
      View in: PubMed   Mentions: 134     Fields:    Translation:AnimalsCells
    19. A Case of Hypercalcemia and Overexpression of CYP27B1 in Skeletal Muscle Lesions in a Patient with HIV Infection After Cosmetic Injections with Polymethylmethacrylate (PMMA) for Wasting. Calcif Tissue Int. 2015 Dec; 97(6):634-9. Hindi SM, Wang Y, Jones KD, Nussbaum JC, Chang Y, Masharani U, Bikle D, Shoback DM, Hsiao EC. PMID: 26253396; PMCID: PMC4861400.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    20. Group 2 innate lymphoid cells utilize the IRF4-IL-9 module to coordinate epithelial cell maintenance of lung homeostasis. Mucosal Immunol. 2016 Jan; 9(1):275-86. Mohapatra A, Van Dyken SJ, Schneider C, Nussbaum JC, Liang HE, Locksley RM. PMID: 26129648; PMCID: PMC4698110.
      View in: PubMed   Mentions: 104     Fields:    Translation:AnimalsCells
    21. Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. Immunity. 2015 Jul 21; 43(1):161-74. Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, Bluestone JA, Locksley RM. PMID: 26092469; PMCID: PMC4512852.
      View in: PubMed   Mentions: 233     Fields:    Translation:AnimalsCells
    22. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell. 2015 Jan 15; 160(1-2):74-87. Lee MW, Odegaard JI, Mukundan L, Qiu Y, Molofsky AB, Nussbaum JC, Yun K, Locksley RM, Chawla A. PMID: 25543153; PMCID: PMC4297518.
      View in: PubMed   Mentions: 362     Fields:    Translation:AnimalsCells
    23. Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and γδ T cells. Immunity. 2014 Mar 20; 40(3):414-24. Van Dyken SJ, Mohapatra A, Nussbaum JC, Molofsky AB, Thornton EE, Ziegler SF, McKenzie AN, Krummel MF, Liang HE, Locksley RM. PMID: 24631157; PMCID: PMC4019510.
      View in: PubMed   Mentions: 130     Fields:    Translation:AnimalsCells
    24. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014 Mar; 58(5):736-45. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, Longley N, Muzoora C, Phulusa J, Taseera K, Kanyembe C, Wilson D, Hosseinipour MC, Brouwer AE, Limmathurotsakul D, White N, van der Horst C, Wood R, Meintjes G, Bradley J, Jaffar S, Harrison T. PMID: 24319084; PMCID: PMC3922213.
      View in: PubMed   Mentions: 194     Fields:    Translation:Humans
    25. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 2013 Oct 10; 502(7470):245-8. Nussbaum JC, Van Dyken SJ, von Moltke J, Cheng LE, Mohapatra A, Molofsky AB, Thornton EE, Krummel MF, Chawla A, Liang HE, Locksley RM. PMID: 24037376; PMCID: PMC3795960.
      View in: PubMed   Mentions: 543     Fields:    Translation:AnimalsCells
    26. 265 Cooperative activation of innate lymphoid type 2 cells (ILC2) by epithelial cytokines in response to chitin. Cytokine. 2013 Sep 1; 63(3):306. Van Dyken VS, Mohapatra MA, Nussbaum NJ, Liang LH, Locksley LR. .
      View in: Publisher Site   Mentions:
    27. Type 2 innate lymphoid cells constitutively express arginase-I in the naive and inflamed lung. J Leukoc Biol. 2013 Nov; 94(5):877-84. Bando JK, Nussbaum JC, Liang HE, Locksley RM. PMID: 23924659; PMCID: PMC3800063.
      View in: PubMed   Mentions: 58     Fields:    Translation:AnimalsCells
    28. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med. 2013 Mar 11; 210(3):535-49. Molofsky AB, Nussbaum JC, Liang HE, Van Dyken SJ, Cheng LE, Mohapatra A, Chawla A, Locksley RM. PMID: 23420878; PMCID: PMC3600903.
      View in: PubMed   Mentions: 456     Fields:    Translation:AnimalsCells
    29. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS. 2012 Jul 17; 26(11):1363-70. Jackson AT, Nussbaum JC, Phulusa J, Namarika D, Chikasema M, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, van der Horst C, Harrison TS. PMID: 22526517; PMCID: PMC3776948.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    30. Infectious (Non)tolerance--frustrated commensalism gone awry? Cold Spring Harb Perspect Biol. 2012 May 01; 4(5). Nussbaum JC, Locksley RM. PMID: 22456498; PMCID: PMC3331693.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    31. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010 Feb 01; 50(3):338-44. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, Kamwendo D, van der Horst CM, Harrison TS. PMID: 20038244; PMCID: PMC2805957.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimals
    32. Cryptococcus neoformans virulence gene discovery through insertional mutagenesis. Eukaryot Cell. 2004 Apr; 3(2):420-9. Idnurm A, Reedy JL, Nussbaum JC, Heitman J. PMID: 15075272; PMCID: PMC387659.
      View in: PubMed   Mentions: 99     Fields:    Translation:AnimalsCells
    33. Enzymes that counteract nitrosative stress promote fungal virulence. Curr Biol. 2003 Nov 11; 13(22):1963-8. de Jesús-Berríos M, Liu L, Nussbaum JC, Cox GM, Stamler JS, Heitman J. PMID: 14614821.
      View in: PubMed   Mentions: 84     Fields:    Translation:AnimalsCells
    34. 2006 expressed-sequence tags derived from human chromosome 7-enriched cDNA libraries. Genome Res. 1997 Mar; 7(3):281-92. Touchman JW, Bouffard GG, Weintraub LA, Idol JR, Wang L, Robbins CM, Nussbaum JC, Lovett M, Green ED. PMID: 9074931.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    Jesse's Networks
    Concepts (196)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (23)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.